A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Summary. Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.

Depending on the blood sugar level, they promote the release of insulin from the pancreas – a mechanism known as the incretin effect. At the same time, GLP-1 inhibits the release of glucagon, a ...

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

1,036 (80%) reported awareness of GLP-1 / GIP RAs, with women significantly more likely that men to report both higher awareness (87% vs. 68%) and excellent understanding (20% vs. 8%) of GLP-1 ...

The main function of the hormone is to stimulate the release of insulin from the pancreas. Together with i.a. GLP-1, GIP is essential for the regulation of insulin in the body.